GLI1 and neoplasm: Despite widespread expression of GLI1 in tumors, considered to be a marker of HH activation, HH inhibitors have solely been granted FDA approval for the treatment of advanced basal cell carcinoma of the skin, a type of tumor that bears activating mutations of the HH pathway25.